Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending January 2014. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMRs) under the GSK 401K plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding internal plan transactions rather than a financial performance report.
Material Changes
The filing details a revaluation of the cash element of a notional investment held within the GSK 401K plan. This resulted in an increase in the notional allocation of GSK American Depositary Shares (ADSs) on January 17, 2014, at a price of $54.10 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports on the notification of specific share allocations in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Important Facts for Investors
- Transaction Date: January 17, 2014.
- Transaction Price: $54.10 per ADS.
- Director Allocation: Dr. M M Slaoui received a notional increase of 15 ADSs.
- Connected Person Allocation: Dr. K Slaoui received a notional increase of 3 ADSs.
- Plan Context: These allocations are part of the GSK 401K plan and represent notional holdings, not direct market purchases by the individuals.